[HTML][HTML] Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care …
MG Thompson - MMWR. Morbidity and Mortality Weekly Report, 2021 - cdc.gov
MG Thompson
MMWR. Morbidity and Mortality Weekly Report, 2021•cdc.govProspective cohorts of 3,950 health care personnel, first responders, and other essential and
frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under
real-world conditions, mRNA vaccine effectiveness of full immunization (≥ 14 days after
second dose) was 90% against SARS-CoV-2 infections regardless of symptom status;
vaccine effectiveness of partial immunization (≥ 14 days after first dose but before second
dose) was 80%.
frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under
real-world conditions, mRNA vaccine effectiveness of full immunization (≥ 14 days after
second dose) was 90% against SARS-CoV-2 infections regardless of symptom status;
vaccine effectiveness of partial immunization (≥ 14 days after first dose but before second
dose) was 80%.
Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥ 14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (≥ 14 days after first dose but before second dose) was 80%.
cdc.gov